Treatment of stroke related refractory brain edema using mixed vasopressin antagonism: A case report and review of the literature

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Hedna, Vishnumurthy Shushrutha ^a   Bidari, Sharathchandra ^b   Gubernick, David ^a   Ansari, Saeed ^a   Satriotomo, Irawan ^a   Khan, Asif A ^c   Qureshi, Adnan I ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Departments of Surgery University of Florida ^*  (United States)

Author keywords

Cerebral edema; Conivaptan; Mixed vasopressin antagonism; Stroke; Vasopressin

Indexed keywords

CONIVAPTAN; SODIUM; SODIUM CHLORIDE; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ADULT; ANGIOPLASTY; ARTICLE; ASPIRATION PNEUMONIA; BASILAR ARTERY; BRAIN ARTERY ANEURYSM; BRAIN EDEMA; BRAIN HEMORRHAGE; CASE REPORT; CAUCASIAN; CEREBROVASCULAR ACCIDENT; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIPLOPIA; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DYSARTHRIA; ELECTIVE SURGERY; ENDOVASCULAR ANEURYSM REPAIR; EPILEPTIC STATE; EXTUBATION; FACIAL NERVE PARALYSIS; HEADACHE; HEMIPARESIS; HEMIPLEGIA; HUMAN; INTERNUCLEAR OPHTHALMOPLEGIA; LOADING DRUG DOSE; MALE; MESENCEPHALON; MIDDLE AGED; NAUSEA AND VOMITING; NEUROIMAGING; PALLIATIVE THERAPY; PARESTHESIA; PRIMARY MOTOR CORTEX; RESPIRATORY FAILURE; SERUM OSMOLALITY; SODIUM BLOOD LEVEL; SOMNOLENCE; THALAMUS; TONIC CLONIC SEIZURE; COMPLICATION;

ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; BRAIN EDEMA; HUMANS; MALE; MIDDLE AGED; STROKE;

EID: 84923877314     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-014-0213-0     Document Type: Article

References (27)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, et al: Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125(1):188-197.
2. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R: 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol 1996, 53(4):309-315.
3. Vahedi K, Hofmeijer J, Juettler E, Vicaut E, George B, Algra A, Amelink GJ, Schmiedeck P, Schwab S, Rothwell PM, Bousser MG, van der Worp HB, Hacke W: Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet neurology 2007, 6(3):215-222.
4. Walcott BP, Kahle KT, Simard JM: Novel treatment targets for cerebral edema. Neurotherapeutics 2012, 9(1):65-72.
5. Strandvik GF: Hypertonic saline in critical care: a review of the literature and guidelines for use in hypotensive states and raised intracranial pressure. Anaesthesia 2009, 64(9):990-1003.
6. Barreca T, Gandolfo C, Corsini G, Del Sette M, Cataldi A, Rolandi E, Franceschini R: Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc Dis 2001, 11(2):113-118.
7. Chang Y, Chen TY, Chen CH, Crain BJ, Toung TJ, Bhardwaj A: Plasma arginine-vasopressin following experimental stroke: effect of osmotherapy. J Appl Physiol (1985) 2006, 100(5):1445-1451.
8. Vakili A, Kataoka H, Plesnila N: Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia. J Cerebr Blood Flow Metabol 2005, 25(8):1012-1019.
9. Decaux G, Soupart A, Vassart G: Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008, 371(9624):1624-1632.
10. Walter KA: Conivaptan: new treatment for hyponatremia. Am J Health Syst Pharm 2007, 64(13):1385-1395.
11. Okuno K, Taya K, Marmarou CR, Ozisik P, Fazzina G, Kleindienst A, Gulsen S, Marmarou A: The modulation of aquaporin-4 by using PKC-activator (phorbol myristate acetate) and V1a receptor antagonist (SR49059) following middle cerebral artery occlusion/reperfusion in the rat. Acta Neurochirurgica Supplement 2008, 102:431-436.
12. Aditya S, Rattan A: Vaptans: a new option in the management of hyponatremia. Int J Basic Appl Innovat Res 2012, 2(2):77-83.
13. Hline SS, Pham PT, Pham PT, Aung MH, Pham PM, Pham PC: Conivaptan: a step forward in the treatment of hyponatremia? Therapeut Clin Risk Manag 2008, 4(2):315-326.
14. Potts MB, DeGiacomo AF, Deragopian L, Blevins LS Jr: Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion. Neurosurgery 2011, 69(2):268-273.
15. Jones RC, Rajasekaran S, Rayburn M, Tobias JD, Kelsey RM, Wetzel GT, Cabrera AG: Initial experience with conivaptan use in critically ill infants with cardiac disease. J Pediatr Pharmacol Therapeut 2012, 17(1):78-83.
16. Liu X, Nakayama S, Amiry-Moghaddam M, Ottersen OP, Bhardwaj A: Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke. Neurocritical care 2010, 12(1):124-131.
17. Rosenberg GA, Estrada E, Kyner WT: Vasopressin-induced brain edema is mediated by the V1 receptor. Adv Neurol 1990, 52:149-154.
18. Shuaib A, Xu Wang C, Yang T, Noor R: Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke 2002, 33(12):3033-3037.
19. Manaenko A, Fathali N, Khatibi NH, Lekic T, Hasegawa Y, Martin R, Tang J, Zhang JH: Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury. Neurochem Int 2011, 58(4):542-548.
20. Manaenko A, Fathali N, Khatibi NH, Lekic T, Shum KJ, Martin R, Zhang JH, Tang J: Post-treatment with SR49059 improves outcomes following an intracerebral hemorrhagic stroke in mice. Acta Neurochirurgica Supplement 2011, 111:191-196.
21. Salvucci A, Armstead WM: Vasopressin impairs K(ATP) and K(ca) channel function after brain injury. Brain Res 2000, 887(2):406-412.
22. Croiset G, De Wied D: Proconvulsive effect of vasopressin; mediation by a putative V2 receptor subtype in the central nervous system. Brain Res 1997, 759(1):18-23.
23. Landgraf R, Ramirez AD, Ramirez VD: The positive feedback action of vasopressin on its own release from rat septal tissue in vitro is receptor-mediated. Brain Res 1991, 545(1-2):137-141.
24. Wotjak CT, Ludwig M, Landgraf R: Vasopressin facilitates its own release within the rat supraoptic nucleus in vivo. Neuroreport 1994, 5(10):1181-1184.
25. Yeung PK, Lo AC, Leung JW, Chung SS, Chung SK: Targeted overexpression of endothelin-1 in astrocytes leads to more severe cytotoxic brain edema and higher mortality. J Cerebr Blood Flow Metabol 2009, 29(12):1891-1902.
26. Laszlo FA, Varga C, Nakamura S: Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage. Eur J Pharmacol 1999, 364(2-3):115-122.
27. Ameli PA, Ameli NJ, Gubernick DM, Ansari S, Mohan S, Satriotomo I, Buckley AK, Maxwell CW Jr, Nayak VH, Shushrutha Hedna V: Role of vasopressin and its antagonism in stroke related edema. J Neurosci Res 2014, 92(9):1091-1099.